Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
申请人:——
公开号:US20020025968A1
公开(公告)日:2002-02-28
A method for inhibiting neoplastic cells and related conditions by exposing them to 4-aminoquinazoline derivatives.
通过将肿瘤细胞暴露于4-氨基喹噁啉衍生物来抑制肿瘤细胞和相关疾病的方法。
Substituted 2-arylquinazolines as fungicides
申请人:FMC Corporation
公开号:US03998951A1
公开(公告)日:1976-12-21
Fungicidal compositions based on substituted 2-arylquinazolines exhibit antifungal activity particularly against rusts and mildews. The synthesis of new compounds is described and the utility of antifungal compositions is exemplified.
Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
作者:Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani
DOI:10.1021/jm00018a014
日期:1995.9
Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.
Researches on benzodiazines
作者:I. Ya. Postovskii、N. N. Vereshchagina、S. L. Mertsalov
DOI:10.1007/bf00955606
日期:——
ESSAWY, A., REV. ROUM. CHIM., 1982, 27, N 3, 415-421